Zinforo™ (Ceftarolinfosamil) – Ein neues Beta-Laktam-Cephalosporin mit MRSA-Aktivität

Schlüsselwörter

Ceftarolin - Ceftriaxon - ambulant erworbene Pneumonie (CAP) - FOCUS 1, FOCUS 2

Keywords

ceftaroline - ceftriaxone - community-acquired pneumonia (CAP) - FOCUS 1, FOCUS 2

• Literatur

• 1 Eckburg P, Friedland HD, Llorens L et al. Day 4 Clinical Response of Ceftaroline Fosamil Versus Ceftriaxone for Community-Acquired Bacterial Pneumonia. Infect Clin Dis Pract 2012; 20: 254-260
• 2 File Jr TM, Low DE, Eckburg PB et al. FOCUS 1: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia. J Antimicrob Chemother 2011; 66 (Suppl. 03) iii19-32
• 3 File Jr TM, Low DE, Eckburg PB et al. Integrated analysis of FOCUS 1 and FOCUS 2: randomized, doubled-blinded, multicenter phase 3 trials of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in patients with community-acquired pneumonia. Clin Infect Dis 2010; 51: 1395-1405
• 4 Kothe H, Bauer T, Marre R et al. Outcome of community-acquired pneumonia: influence of age, residence status and antimicrobial treatment. Eur Respir J 2008; 32: 139-146
• 5 Low DE, File Jr TM, Eckburg PB et al. FOCUS 2: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia. J Antimicrob Chemother 2011; 66 (Suppl. 03) iii33-44
• 6 Polverino E, Dambrava P, Cillóniz C et al. Nursing home-acquired pneumonia: a 10 year single-centre experience. Thorax 2010; 65: 354-359